|
Cholinesterases inhibitors for treating Alzheimer’s disease
|
|
| Author:
|
RANIA BAKR
|
| Abstract:
|
Alzheimer’s disease is a chronic neurodegenerative disorder marked with gradual decline in memory and higher cortical action leading to total deterioration of cognitive and intellectual functions. The complete causation of the disease still remains unknown. Many targets might inhibit Alzheimer’s disease includes, gamma-secretase inhibitors, antibetaamyloid immunization), kinase inhibitors, antioxidants, brain iron homeostasis (e.g., chelating agents) are identified. Unfortunately, these targets were failed clinically, but it was found that the agents targeting the acetylcholine (acetylcholinesterase (AChE) and butyryl cholinesterase (BuChE) inhibitors) were approved clinically. As acetylcholine deficiency is the main cause of dementia and cognitive disorders in Alzheimer’s Disease, the present review focuses on the new advancement for inhibiting acetylcholine including many classes of inhibitors such as carbamate, pyridine, coumarin and acridine derivatives and their structural activity relationships reported till date.
|
| Keyword:
|
Acetyl cholinesterase; Butyryl cholinesterase; Alzheimer’s disease; Coumarin derivatives; Pyridine scaffold, Acridine.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.12.04.114
|
| Download:
|
Request For Article
|
|
|